Hikal Q1 FY27: Early recovery, but margins still carrying the weight of remediation

Hikal started FY27 with a quarter that management described as a transition from regulatory-led disruption to execution-led growth. For Q1 FY27, consolidated revenue came in at 403 crore, with EBITDA of 37 crore and an EBITDA margin of 9.2%. The company remained loss-making at the net level, reporting PAT of -7 crore.

The quarter’s headline was not just the numbers, but the reasons behind them. In pharmaceuticals, Hikal continued to work through its US FDA remediation plan, which included planned shutdowns and incremental compliance work that slowed near-term sales. In crop protection, ordering remained cautious as customers continued inventory adjustments, while input costs rose due to geopolitical volatility. Against this, management pointed to improving customer demand patterns, a gradual recovery in regulated-market demand, and new capability investments like the Pune cGMP pilot plant.

Q1 FY27 performance: growth in pharma, pressure in crop

Pharmaceuticals contributed 58% of consolidated revenue in Q1 FY27, with revenue of 233 crore, up 15.2% year on year. The segment moved back to positive EBIT at 8 crore after a loss in Q1 FY26, though the margin remained modest. Within pharma, the mix tilted further toward CDMO, which made up 59% of segment revenue, while own products made up 41%.

Crop protection delivered revenue of 170 crore, down sequentially, with EBIT turning negative at -6 crore. Management attributed the profitability decline to a combination of subdued export CDMO demand due to customer inventory adjustments, continued pricing pressure linked to excess supply from China, and a sharp rise in raw material and fuel costs. On the call, management stated that raw material cost inflation impacted the crop business by around 7 to 8 crore in the quarter.

Financial summary (Consolidated)

The company reported exceptional income of 9 crore in Q1 FY27, relating to reversal of excess provision made earlier for implementation of the new labour code.

Building a higher-value pharma platform

The most persistent theme in management commentary was that the pharma business is being repositioned toward differentiated APIs, specialty therapies, and deeper CDMO engagement. Hikal highlighted focus areas that include oncology, CNS, gastroenterology, anti-diabetics, and complex chemistries.

The company also emphasized an improvement in regulatory confidence signals even as the US FDA remediation continues. Management stated that over the last 12 months it has not lost a single customer order, and that multiple global regulatory authorities and customer audits have cleared and re-approved its facilities. The investor presentation separately highlighted that more than 100 customer audits were passed at the Bangalore facility.

A critical operational lever is product development throughput. Hikal stated that its DMF filing cadence is increasing to 5 to 6 filings per year versus 2 to 3 historically, supported by new infrastructure. Management also referenced an even higher potential cadence of 6 to 7 filings per year as capabilities expand.

Strategic capability: Pune cGMP pilot plant

The recently commissioned Pune cGMP compliant pilot plant is being positioned as a key bridge between R and D and commercial manufacturing. Management described it as enabling process development, scale-up, technology transfer, and clinical-stage manufacturing. The strategic benefit is customer access earlier in the development cycle, improved conversion of development programs into commercial CDMO contracts, and greater customer stickiness.

Crop protection: recovery exists, but pricing and costs remain headwinds

In crop protection, management’s commentary was notably cautious. While domestic own products showed sequential growth driven by higher volumes, export CDMO demand remained weak due to customer inventory adjustments. The broader industry context was described as a volume-led recovery, with distributors buying on a just-in-time basis rather than restocking.

Pricing pressure remains a structural issue. Management pointed to excess supply from China as a key factor limiting pricing power, even as global channel inventories have largely normalized after multiple years of destocking.

Hikal’s response is operational rather than expansionary. Management said the company is focusing on efficiency initiatives including automation, backward integration, solvent recovery, yield improvement, and asset utilization. It also noted selective debottlenecking and capacity investments backed by long-term contracts.

Portfolio diversification: Animal Health and Personal Care

Beyond the two legacy divisions, Hikal is building Animal Health and Personal Care as additional growth drivers.

Animal Health was described as resilient in Q1 FY27, supported by stronger partnerships, new program commercialization, and a pipeline of advanced intermediates and NCEs. Management reiterated its target for the business to reach 400 crore plus revenue by FY30 and stated that it expects 20% plus EBITDA margins once operational leverage is achieved.

Personal Care reached an operational milestone with the commissioning of a dedicated manufacturing line at Panoli. Commercial production has commenced, and management expects revenue contribution by the end of FY27. The guidance shared on the call suggests that after FY27, the business could cross 200 crore in revenue over the next three years. Management also stated that the margin profile is expected to be over 20% EBITDA.

Capital allocation, balance sheet, and the remediation overhang

Management stated that over the last four years, the company has invested around 900 crore in capex, including approximately 300 crore of maintenance capex and about 600 crore of growth capex. One of the larger investments, an agrochemical manufacturing plant, was partly impaired in Q4 FY26 and is now being retooled into a multipurpose pharma and animal health CDMO facility. Management said this retooling can reduce execution timelines by nearly 12 months for new programs.

On leverage, management stated that net debt reduced from around 815 crore in FY24 to 685 crore by end of FY26, and that debt to equity was around 0.53.

The key near-term swing factor remains the US FDA remediation. Management said remediation costs are still depressing EBITDA, and that more meaningful margin improvement should become visible in FY28 and beyond once remediation costs roll off.

Outlook: quantified guidance for FY27

Management provided explicit guidance for FY27:

• Revenue growth of approximately 14% to 16% for the full year
• EBITDA growth of approximately 25% to 30%

Management expects momentum to strengthen through FY27, with acceleration in H2, supported by improving demand visibility, increased CDMO contribution, and progress toward US FDA re-inspection, which it expects toward the end of FY27 (with possible timing slippage by a few months).

Takeaways for investors

Hikal’s Q1 FY27 shows early signs of recovery, led by pharmaceuticals, while crop protection remains weighed down by pricing pressure and volatile input costs. The bigger story is strategic: the company is trying to move toward higher-value, regulated and innovation-led segments through pharma CDMO, Animal Health, and Personal Care.

The next key checkpoints are the progress toward US FDA re-inspection in FY27, the pace of DMF filings and CDMO conversions supported by the Pune pilot plant, and whether the newer verticals scale toward management’s medium-term targets.